Navigation Links
BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
Date:10/28/2008

A Single Dose of Peramivir is Effective and Well-Tolerated at Both 300 mg and 600 mg Dose Levels

BIRMINGHAM, Ala., Oct. 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that a double-blind, placebo-controlled, Phase 2 study of intravenous (i.v.) peramivir, administered via a single dose injection in outpatients with acute, uncomplicated influenza, met its primary endpoint of time to alleviation of symptoms for both the 300 mg dose (p=0.0046) and 600 mg dose (p=0.0046). The study was sponsored by BioCryst's partner for peramivir, Shionogi & Co., Ltd.

The poster titled, "A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients" (Poster Session # 302: Respiratory Viruses I: Influenza and RSV) will be presented on Tuesday, October 28 from 12:15 p.m. - 1:15 p.m. Eastern Time in Hall C by Dr. Shigeru Kohno, Dean, Nagasaki University Graduate School of Medicine and Professor, Infection Immunology Department, Nagasaki University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

"This Phase 2 study was a critical test of peramivir, which demonstrated for the first time that a single administration of this potent neuraminidase inhibitor can be effective in treating seasonal influenza," said Dr. William P. Sheridan, Chief Medical Officer of BioCryst. "The promising data in outpatient influenza highlights the potential of the compound as a novel and effective influenza therapy and we look forward to learning more about the clinical advantages of peramivir in the upcoming Shionogi-sponsored Phase 3 program."

The randomized, double-blind, placebo-controlled, Phase 2 study conducted in Japan enrolled 300 patients age 20 to 64, who
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
2. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
3. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
4. LCA-Vision Reports Third Quarter 2008 Financial Results
5. Universal Health Services, Inc. Reports 2008 Third Quarter Results
6. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
7. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
8. WellPoint Reports Third Quarter 2008 Results
9. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
10. Schering-Plough Reports Financial Results for Third Quarter of 2008
11. Quest Diagnostics Reports Growth in Revenue and Earnings for Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Isabel Healthcare will ... Professions (ASAHP) Conference on October 22-24 in Las Vegas, ... in a panel discussion on Technology in Health Professions ... provides a diagnostic decision support tool and clinical education ... of students and clinical learners. The Isabel tools help ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... EurekAlert! in 2010 was the discovery of a "golden ... finding put forth the new suggestion that matter on ... patterns as opposed to chaos. Stories on the ... EurekAlert! users in 2010. The most popular topics varied ...
... HealthDay Reporter , TUESDAY, March 22 (HealthDay News) -- ... reduce the risk of developing high blood pressure, a new ... risk of developing hypertension in those who consumed whole grain ... researcher Dr. Jinesh Kochar, of Beth Israel Deaconess Medical Center ...
... March 23 (HealthDay News) -- Reducing the workload of U.S. ... has not had a negative effect on patient safety and ... a new study contends. The findings, which stem from ... and United Kingdom, challenge concerns expressed by medical professionals that ...
... Chase, MD A recent study accepted for publication in The ... (JCEM) found that higher levels of perfluorocarbons (PFCs) in the ... in women between 42 and 64 years old. Women in ... significantly lower concentrations of estrogen when compared to women who ...
... of a young, apparently healthy athlete dying on the court or ... at Fennville High School, who died of cardiac arrest from an ... if enough is being done to identify athletes at risk for ... program to help prevent sudden cardiac death, but there is not ...
... In 1998, a study linking the measles, mumps and ... respected medical journal. For a decade, the study grabbed headlines ... and those with autistic children agonized that they allowed an ... was a fraud. The paper was retracted 12 years later, ...
Cached Medicine News:Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 2Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 3Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 4Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 5Health News:Whole Grain Cereal May Help Control Blood Pressure 2Health News:Whole Grain Cereal May Help Control Blood Pressure 3Health News:Exposure to chemicals in environment associated with onset of early menopause 2Health News:Do all student athletes need heart screenings? 2Health News:Do all student athletes need heart screenings? 3Health News:Research practices must be changed to minimize fraud, deception 2
(Date:10/22/2014)... Investor-Edge has initiated coverage on ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ... Idera Pharmaceuticals Inc. (NASDAQ: IDRA ), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,419.48, up 2.40%, the Dow Jones ...
(Date:10/22/2014)... RIDGE, N.J. , Oct. 22, 2014 /PRNewswire/ ... (RMANJ), a world-renowned leader in the field of ... rapid approach to embryonic screening. The research abstract, ... Society for Reproductive Medicine (ASRM) meeting in ... screening (CCS) and single gene defect (SGD) pre-implantation ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... , PALM CITY, Fla., Dec, 17 Connectyx Technologies ... it has formed a distribution partnership with United States ... Supplies, Respiratory Supplies and Medications as well as Bladder ... Terms of the partnership were not disclosed, however Connectyx ...
... 17 Instacare Corp. (OTC Bulletin Board: ISCR) a ... and diagnostics and at home testing products for the ... e-health technologies and revolutionary cell phone centric technologies and ... of its Fiscal 2010 guidance, the Board has determined ...
Cached Medicine Technology:Connectyx Announces Distribution Partnership with United States Medical Supply 2Connectyx Announces Distribution Partnership with United States Medical Supply 3Instacare Corp. Board of Directors Sets Growth Plans for 2010 2
... is the first and only ... 3 layers of the tear ... that lubricates and protects the ... helps seal in moisture and ...
...
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
ALOCRIL® ophthalmic solution is a prescription eye drop for itchy allergy eyes. ALOCRIL® provides control beyond relief by providing continuous symptom control throughout the allergy season....
Medicine Products: